| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
PAPER |
1 Section of Geriatric Psychiatry, Psychiatric Hospital of Rogaland, Stavanger, Norway
2 Department of Geriatric Medicine, Ullevål Hospital, Oslo, Norway
3 Department of Neurology, Central Hospital of Stavanger, Norway
Correspondence to:
Correspondence to:
Dr D Aarsland, Section of Geriatric Psychiatry, Psychiatric Hospital of Rogaland, Arm. Hansen v 20, 4095 Stavanger, Norway;
aarsland{at}netpower.no
Objective: To study the safety and efficacy of the cholinesterase inhibitor donepezil in patients with Parkinson's disease (PD) and cognitive impairment.
Methods: This was a double blind, randomised and placebo controlled, crossover study in which 14 patients with PD and cognitive impairment received donepezil (5 or 10 mg per day) or matching placebo during two sequential periods lasting 10 weeks each. The primary outcome measures were the mini mental state examination (MMSE) score, the clinician's interview based impression of change plus caregiver input (CIBIC+) score, and the motor subscale of the unified Parkinson's disease rating scale (UPDRS).
Results: Two patients on donepezil (14%) dropped out after one and four weeks of the first treatment period because of peripheral cholinergic side effects, otherwise the adverse effects were few and not severe. Carryover or residual effects were not observed. Parkinsonism did not increase during donepezil treatment. After 10 weeks of treatment, the mean MMSE score was increased by 2.1(SD 2.7) points on donepezil and 0.3 (SD 3.2) points on placebo, and the CIBIC+ score was 3.3 (SD 0.9) on donepezil and 4.1 (SD 0.8) on placebo. Statistical analysis of the repeated measurements and crossover study design showed significant effects of donepezil compared with placebo for MMSE (p=0.013) and CIBIC+ (p=0.034). Five (42%) patients on donepezil and two (17%) on placebo were rated as improved on the basis of the CIBIC+ score.
Conclusions: Donepezil improves cognition, and seems to be well tolerated and not to worsen parkinsonism in patients with cognitive impairment.
Keywords: Parkinson's disease; cognitive impairment; donepezil
Abbreviations: PD, Parkinson's disease; MMSE, mini mental state examination; UPDRS, unified Parkinson's disease rating scale; NPI, neuropsychiatric inventory; DLB, dementia with Lewy bodies
This article has been cited by other articles:
|
|
 |
|
  J. J. Chen, D. P. Trombetta, and H. H. Fernandez Palliative Management of Parkinson Disease: Focus on Nonmotor, Distressing Symptoms Journal of Pharmacy Practice, August 1, 2008; 21(4): 262 - 272. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Weintraub and H. I. Hurtig Presentation and Management of Psychosis in Parkinson's Disease and Dementia With Lewy Bodies Am J Psychiatry, October 1, 2007; 164(10): 1491 - 1498. [Full Text] [PDF]
|
|
|
|
 |
|
 C. F. Lippa, J. E. Duda, M. Grossman, H. I. Hurtig, D. Aarsland, B. F. Boeve, D. J. Brooks, D. W. Dickson, B. Dubois, M. Emre, et al. DLB and PDD boundary issues: Diagnosis, treatment, molecular pathology, and biomarkers Neurology, March 13, 2007; 68(11): 812 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Ferreri, C. Agbokou, and S. Gauthier Recognition and management of neuropsychiatric complications in Parkinson's disease Can. Med. Assoc. J., December 5, 2006; 175(12): 1545 - 1552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Burns and J. O'Brien Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol, November 1, 2006; 20(6): 732 - 755. [Abstract] [PDF]
|
|
|
|
|
|
E. Cubo, K. M. Shannon, D. Tracy, J. A. Jaglin, B. A. Bernard, J. Wuu, and S. E. Leurgans Effect of donepezil on motor and cognitive function in Huntington disease. Neurology, October 10, 2006; 67(7): 1268 - 1271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Miyasaki, K. Shannon, V. Voon, B. Ravina, G. Kleiner-Fisman, K. Anderson, L. M. Shulman, G. Gronseth, and W. J. Weiner Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, April 11, 2006; 66(7): 996 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Samuel, I. Maidment, M. Boustani, and C. Fox Clinical management of Parkinson's disease dementia: pitfalls and progress Advan. Psychiatr. Treat., March 1, 2006; 12(2): 121 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Weintraub and M. B. Stern Psychiatric Complications in Parkinson Disease Am J Geriatr Psychiatry, October 1, 2005; 13(10): 844 - 851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J L Cummings Cholinesterase inhibitors for treatment of dementia associated with Parkinson's disease J. Neurol. Neurosurg. Psychiatry, July 1, 2005; 76(7): 903 - 904. [Full Text] [PDF]
|
|
|
|
|
|
B Ravina, M Putt, A Siderowf, J T Farrar, M Gillespie, A Crawley, H H Fernandez, M M Trieschmann, S Reichwein, and T Simuni Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study J. Neurol. Neurosurg. Psychiatry, July 1, 2005; 76(7): 934 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. H. Adler and M. J. Thorpy Sleep issues in Parkinson's disease Neurology, June 28, 2005; 64(12_suppl_3): S12 - S20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Chow Rivastigmine modestly improves dementia associated with Parkinson's disease, but has important adverse effects Evid. Based Ment. Health, May 1, 2005; 8(2): 41 - 41. [Full Text] [PDF]
|
|
|
|
|
|
S J G Lewis, T Foltynie, A D Blackwell, T W Robbins, A M Owen, and R A Barker Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach J. Neurol. Neurosurg. Psychiatry, March 1, 2005; 76(3): 343 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. P. Mosimann, G. Mather, K. A. Wesnes, J. T. O'Brien, D. J. Burn, and I. G. McKeith Visual perception in Parkinson disease dementia and dementia with Lewy bodies Neurology, December 14, 2004; 63(11): 2091 - 2096. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Emre, D. Aarsland, A. Albanese, E. J. Byrne, G. Deuschl, P. P. De Deyn, F. Durif, J. Kulisevsky, T. van Laar, A. Lees, et al. Rivastigmine for Dementia Associated with Parkinson's Disease N. Engl. J. Med., December 9, 2004; 351(24): 2509 - 2518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Krupp, C. Christodoulou, P. Melville, W. F. Scherl, W. S. MacAllister, and L. E. Elkins Donepezil improved memory in multiple sclerosis in a randomized clinical trial Neurology, November 9, 2004; 63(9): 1579 - 1585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Wint, M. S. Okun, and H. H. Fernandez Psychosis in Parkinson's Disease J Geriatr Psychiatry Neurol, September 1, 2004; 17(3): 127 - 136. [Abstract] [PDF]
|
|
|
|
|
|
D. Aarsland, U. P. Mosimann, and I. G. McKeith Role of Cholinesterase Inhibitors in Parkinson's Disease and dementia with Lewy Bodies J Geriatr Psychiatry Neurol, September 1, 2004; 17(3): 164 - 171. [Abstract] [PDF]
|
|
|
|
|
|
L. Marsh, J. R. Williams, M. Rocco, S. Grill, C. Munro, and T. M. Dawson Psychiatric comorbidities in patients with Parkinson disease and psychosis Neurology, July 27, 2004; 63(2): 293 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Burton, I. G. McKeith, D. J. Burn, E. D. Williams, and J. T. O'Brien Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls Brain, April 1, 2004; 127(4): 791 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Shults Treatments of Parkinson Disease: Circa 2003 Arch Neurol, December 1, 2003; 60(12): 1680 - 1684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Miyasaki, K. Shannon, V. Voon, B. Ravina, G. Kleiner-Fisman, K. Anderson, L. M. Shulman, G. Gronseth, and W. J. Weiner Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, April 11, 2006; 66(7): 996 - 1002. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
